Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma
Autor: | Agnes, Benedict, Robert A, Figlin, Per, Sandström, Ulrika, Harmenberg, Anders, Ullén, Claudie, Charbonneau, Rickard, Sandin, Edit, Remák, Subramanian, Hariharan, Sylvie, Négrier |
---|---|
Rok vydání: | 2011 |
Předmět: |
Male
Niacinamide Indoles Pyridines Cost-Benefit Analysis Antineoplastic Agents Antibodies Monoclonal Humanized Drug Costs Sunitinib Humans Pyrroles Molecular Targeted Therapy Carcinoma Renal Cell Sweden Phenylurea Compounds Benzenesulfonates Antibodies Monoclonal Interferon-alpha Sorafenib Kidney Neoplasms Markov Chains United States Bevacizumab Disease Progression Female Quality-Adjusted Life Years |
Zdroj: | BJU international. 108(5) |
ISSN: | 1464-410X |
Popis: | • To assess the economic value of targeted therapies as first-line metastatic renal cell carcinoma (mRCC) treatment in the US and Sweden by indirect comparison of survival data.• A Markov model simulated disease progression, adverse events and survival with sunitinib vs sorafenib in the US and bevacizumab plus interferon-α (IFN-α) in both countries. • Results, in life-years (LYs), progression-free LYs (PFLYs), quality-adjusted LYs (QALYs) gained and treatment costs (2008 USD) were obtained through deterministic and probabilistic analyses over the patient's lifetime.• Sunitinib was more effective and less costly than sorafenib (gains of 0.52 PFLYs, 0.16 LYs and 0.17 QALYs and savings/patient of $13,576 in the US) and bevacizumab plus IFN-α (gains of 0.19 PFLYs, 0.23 LYs and 0.16 QALYs in both countries and savings/patient of $67,798 and $47,264 in the US and Sweden, respectively). • Results were most influenced by hazard ratios for progression-free and overall survival and treatment costs, making results generalizable across other countries if relative costs were to fall within the ranges of those in the US and Sweden.• The present analyses suggest that first-line mRCC treatment with sunitinib is a cost-effective alternative to sorafenib and bevacizumab plus IFN-α. |
Databáze: | OpenAIRE |
Externí odkaz: |